Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lönnqvist B, Ringdén O, Wahren B
Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Bone Marrow Transplant. 1986 Dec;1(2):185-92.
In this randomized double-blind and placebo controlled trial of 6 months' prophylaxis with acyclovir (ACV) in 42 bone marrow transplant (BMT) recipients, patients receiving ACV had fewer herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections during the prophylaxis compared to the placebo treated patients (P less than 0.05). During the first 6 months after the prophylaxis had been discontinued the frequency of clinical HSV reactivations was low both in the ACV (1/13) and in the placebo (1/13) treated patient groups. Altogether the ACV treated patients had significantly fewer HSV reactivations during the first year after BMT (P less than 0.05). The HSV-specific lymphocyte proliferation response was also lower in the ACV treated group at 3, 6 and 12 months after BMT (P less than 0.05). VZV infections recurred rather frequently, however, after discontinuation of ACV prophylaxis. Therefore no difference was found in the number of VZV infections during the first year after BMT. The VZV-specific lymphocyte proliferation response was significantly lower in the ACV treated group only at 6 months (P less than 0.05). ACV prophylaxis had no effect on the frequency of CMV infections; CMV-specific lymphocyte proliferative responses were not decreased.
在这项针对42名骨髓移植（BMT）受者进行的为期6个月的阿昔洛韦（ACV）预防的随机双盲安慰剂对照试验中，与接受安慰剂治疗的患者相比，接受ACV治疗的患者在预防期间单纯疱疹病毒（HSV）和水痘-带状疱疹病毒（VZV）感染较少（P<0.05）。在预防措施停止后的前6个月内，ACV治疗组（1/13）和安慰剂治疗组（1/13）的临床HSV再激活频率均较低。总体而言，ACV治疗的患者在BMT后的第一年中HSV再激活明显较少（P<0.05）。在BMT后3、6和12个月时，ACV治疗组的HSV特异性淋巴细胞增殖反应也较低（P<0.05）。然而，在停止ACV预防后，VZV感染相当频繁地复发。因此，在BMT后的第一年中，VZV感染的数量没有差异。仅在6个月时，ACV治疗组的VZV特异性淋巴细胞增殖反应明显较低（P<0.05）。ACV预防对巨细胞病毒（CMV）感染的频率没有影响；CMV特异性淋巴细胞增殖反应没有降低。
